Oxford Biomedica Acquires Commercial-Scale Viral Vector Facility
London – October 7, 2025 – Cooley advised Oxford Biomedica (OXB), a global quality and innovation-led cell and gene therapy contract development and manufacturing organization, on its acquisition of a custom-built, state-of-the-art cell and gene therapy viral vector manufacturing facility in North Carolina from RTP Operating, a subsidiary of National Resilience Holdco.
The acquisition expands OXB’s viral vector manufacturing capabilities in the US up to commercial scale, increasing good manufacturing practice capacity and enhancing service offerings to clients across North America.
Lawyers Rita Sobral, Simon Amies and Courtney Thorne led the Cooley team advising OXB.
Cooley previously advised OXB on its 60-million-pound equity raise through a proposed placing of new ordinary shares in August 2025.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.